JP2022523972A5 - - Google Patents
Info
- Publication number
- JP2022523972A5 JP2022523972A5 JP2021552609A JP2021552609A JP2022523972A5 JP 2022523972 A5 JP2022523972 A5 JP 2022523972A5 JP 2021552609 A JP2021552609 A JP 2021552609A JP 2021552609 A JP2021552609 A JP 2021552609A JP 2022523972 A5 JP2022523972 A5 JP 2022523972A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- region
- gipr antagonist
- gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024128733A JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815866P | 2019-03-08 | 2019-03-08 | |
| US62/815,866 | 2019-03-08 | ||
| PCT/US2020/021314 WO2020185533A1 (en) | 2019-03-08 | 2020-03-06 | Growth differentiation factor 15 combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128733A Division JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523972A JP2022523972A (ja) | 2022-04-27 |
| JP2022523972A5 true JP2022523972A5 (enExample) | 2023-02-10 |
| JP7536030B2 JP7536030B2 (ja) | 2024-08-19 |
Family
ID=70166143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552609A Active JP7536030B2 (ja) | 2019-03-08 | 2020-03-06 | 増殖分化因子１５併用療法 |
| JP2024128733A Withdrawn JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128733A Withdrawn JP2024156886A (ja) | 2019-03-08 | 2024-08-05 | 増殖分化因子１５併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220152154A1 (enExample) |
| EP (1) | EP3934679A1 (enExample) |
| JP (2) | JP7536030B2 (enExample) |
| AU (1) | AU2020233876B2 (enExample) |
| CA (1) | CA3131912A1 (enExample) |
| MX (1) | MX2021010737A (enExample) |
| WO (1) | WO2020185533A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN117106085A (zh) * | 2015-12-23 | 2023-11-24 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| US12054527B2 (en) | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| EP4244246A1 (en) * | 2020-11-10 | 2023-09-20 | Amgen Inc. | Novel linkers of multispecific antigen binding domains |
| EP4351627A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| EP4619423A1 (en) * | 2022-11-18 | 2025-09-24 | Yuhan Corporation | Dual function proteins and uses thereof |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69740096D1 (de) | 1996-08-08 | 2011-02-17 | Amylin Pharmaceuticals Inc | Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| JP4798814B2 (ja) | 1997-01-07 | 2011-10-19 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 食物摂取低減用のエキセンジンおよびそのアゴニストの使用 |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| ES2293688T5 (es) | 1997-08-08 | 2011-05-04 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos análogos de la exendina. |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| CA2309356C (en) | 1997-11-14 | 2010-09-21 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
| US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| US20030087820A1 (en) | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| RU2242244C2 (ru) | 1999-01-14 | 2004-12-20 | Амилин Фармасьютикалз, Инк. | Новые композиции агонистов эксендина и способы их введения |
| JP2002538084A (ja) | 1999-01-14 | 2002-11-12 | アミリン・ファーマシューティカルズ，インコーポレイテッド | グルカゴンを抑制する方法 |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| WO2001051078A1 (en) | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| KR20140011431A (ko) | 2004-02-11 | 2014-01-28 | 아밀린 파마슈티칼스, 엘엘씨. | 선택가능한 특성을 갖는 하이브리드 폴리펩티드 |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2899170C (en) * | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| CN106687128B (zh) * | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| CN117106085A (zh) | 2015-12-23 | 2023-11-24 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| EP4480537A3 (en) | 2017-01-17 | 2025-03-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| JP2020533302A (ja) * | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー／エス | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| MY205905A (en) * | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
-
2020
- 2020-03-06 JP JP2021552609A patent/JP7536030B2/ja active Active
- 2020-03-06 WO PCT/US2020/021314 patent/WO2020185533A1/en not_active Ceased
- 2020-03-06 CA CA3131912A patent/CA3131912A1/en active Pending
- 2020-03-06 MX MX2021010737A patent/MX2021010737A/es unknown
- 2020-03-06 EP EP20717008.5A patent/EP3934679A1/en active Pending
- 2020-03-06 AU AU2020233876A patent/AU2020233876B2/en active Active
- 2020-03-06 US US17/436,696 patent/US20220152154A1/en active Pending
-
2024
- 2024-08-05 JP JP2024128733A patent/JP2024156886A/ja not_active Withdrawn